192 related articles for article (PubMed ID: 210235)
61. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
62. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
63. Inhibition of human lung cyclic nucleotide phosphodiesterases by proxyphylline, theophylline and their metabolites.
Selvig K; Bjerve KS
Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):250-2. PubMed ID: 6291318
[TBL] [Abstract][Full Text] [Related]
64. The effects of alkylated xanthines on cyclic AMP accumulation in dog thyroid slices exposed to carbamylcholine.
Miot F; Erneux C; Wells JN; Dumont JE
Mol Pharmacol; 1984 Mar; 25(2):261-6. PubMed ID: 6321949
[TBL] [Abstract][Full Text] [Related]
65. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
Silver PJ; Hamel LT; Perrone MH; Bentley RG; Bushover CR; Evans DB
Eur J Pharmacol; 1988 May; 150(1-2):85-94. PubMed ID: 2841146
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
[TBL] [Abstract][Full Text] [Related]
67. Cyclic GMP and regulation of cyclic nucleotide hydrolysis.
Sonnenburg WK; Beavo JA
Adv Pharmacol; 1994; 26():87-114. PubMed ID: 8038108
[TBL] [Abstract][Full Text] [Related]
68. [Ca2+-calmodulin-activated cyclic nucleotide phosphodiesterase from the soluble fraction of the human brain: Kinetic properties and the effect of the antidepressant pyrazidol and its nitro analog on the enzyme].
Medvedeva MV; Belov AA; Kireeva NN; Bobruskin ID
Biokhimiia; 1993 May; 58(5):798-808. PubMed ID: 8393348
[TBL] [Abstract][Full Text] [Related]
69. Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724.
Henkel-Tigges J; Davis RL
Mol Pharmacol; 1990 Jan; 37(1):7-10. PubMed ID: 2153912
[TBL] [Abstract][Full Text] [Related]
70. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
71. Phosphodiesterase inhibitors.
Boswell-Smith V; Spina D; Page CP
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
[TBL] [Abstract][Full Text] [Related]
72. Differential effects of various phosphodiesterase inhibitors, pyrimidine and purine compounds, and inorganic phosphates on cyclic CMP, cyclic AMP and cyclic GMP phosphodiesterases.
Helfman DM; Kuo JF
Biochem Pharmacol; 1982 Jan; 31(1):43-7. PubMed ID: 6277336
[TBL] [Abstract][Full Text] [Related]
73. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung.
Haynes J; Killilea DW; Peterson PD; Thompson WJ
J Pharmacol Exp Ther; 1996 Feb; 276(2):752-7. PubMed ID: 8632346
[TBL] [Abstract][Full Text] [Related]
74. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
Souness JE; Brazdil R; Diocee BK; Jordan R
Br J Pharmacol; 1989 Nov; 98(3):725-34. PubMed ID: 2480168
[TBL] [Abstract][Full Text] [Related]
75. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
76. cAMP analogs and selective inhibitors used to study low Km Mucor rouxii cAMP phosphodiesterase.
Tomes C; Moreno S
Int J Biochem; 1990; 22(9):1047-51. PubMed ID: 1704316
[TBL] [Abstract][Full Text] [Related]
77. A selective inhibitor of cAMP-specific phosphodiesterase, Ro 20-1724, has no effect on the quantal release of acetylcholine from the mouse phrenic nerve.
Chiou LC; Chang CC
J Pharm Pharmacol; 1988 Feb; 40(2):148-9. PubMed ID: 2897454
[TBL] [Abstract][Full Text] [Related]
78. Actions of papaverine on intestinal smooth muscle and its inhibition of cyclic AMP and cyclic GMP phosphodiesterases.
Miyamoto M; Takayanagi I; Ohkubo H; Takagi K
Jpn J Pharmacol; 1976 Feb; (1):114-7. PubMed ID: 177797
[No Abstract] [Full Text] [Related]
79. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Br J Pharmacol; 1993 Dec; 110(4):1387-94. PubMed ID: 8306078
[TBL] [Abstract][Full Text] [Related]
80. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase.
Wright CD; Kuipers PJ; Kobylarz-Singer D; Devall LJ; Klinkefus BA; Weishaar RE
Biochem Pharmacol; 1990 Aug; 40(4):699-707. PubMed ID: 1696820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
